Shilpa medicare gets CDSCO approval for Tranexamic Acid Spray, Hemostatic Spray. The product is protected by granted patents in India till 2037 and in US, Australia, Russia and South Africa till 2038. Shilpa is continuously pursuing patent prosecution in other countries and for further protection.
Tranexamic acid is a synthetic analog of the amino acid lysine. It serves as an antifibrinolytic by reversibly binding four to five lysine receptor sites on plasminogen. This decreases the conversion of plasminogen to plasmin, preventing fibrin degradation and preserving the framework of fibrin's matrix structure
Tranexamic Acid is Clinically proven in humans and validated in robust swine trauma model. The product is approved for the usage of reducing or preventing hemorrhage and to reduce the need of replacement therapy during accidental and domestic injury.
Tranexamic Acid is useful for quick hemostasis which controls moderate to severe bleeding within minutes. It can be used as potential life-saving tool in first-aid box for traffic or road accidents and battlefield injuries. Apart from that, it is beneficial in civilian prehospital care, emergency medical systems (EMS) and ambulance supply and reduces chances of re-bleeding during transport to hospital.
